Enzon Pharmaceuticals Sells 25% Interest in Hepatitis C Drug
By Business Review Editor
PharmaDeals Review: Vol 2007 Issue 87 (Table of Contents)
Published: 7 Sep-2007
DOI: 10.3833/pdr.v2007i87.294 ISSN: 1756-7874
Section: Royalties
Fulltext:
Abstract
Enzon Pharmaceuticals has sold 25% of its royalty in PEG-Intron® to Drug Royalty for US$92...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS